Pefloxacin

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Pefloxacin
Pefloxacin.svg
Systematic (IUPAC) name
1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid
Pharmacokinetic data
Bioavailability 100%
Protein binding 20–30%
Metabolism Hepatic
Biological half-life 8.6 hours
Excretion Mostly renal, also biliary
Identifiers
CAS Number 70458-92-3 YesY
ATC code J01MA03 (WHO)
PubChem CID: 51081
DrugBank DB00487 YesY
ChemSpider 46291 YesY
UNII 2H52Z9F2Q5 YesY
KEGG D02306 YesY
ChEBI CHEBI:50199 YesY
ChEMBL CHEMBL267648 YesY
Chemical data
Formula C17H20FN3O3
Molecular mass 333.358 g/mol
  • O=C(O)\C2=C\N(c1cc(c(F)cc1C2=O)N3CCN(C)CC3)CC
  • InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24) YesY
  • Key:FHFYDNQZQSQIAI-UHFFFAOYSA-N YesY
  (verify)

Pefloxacin is a quinolone drug used to treat bacterial infections. Pefloxacin has not been approved for use in the United States.

History

Pefloxacin was developed in 1979 and approved in France for human use in 1985.[1]

Licensed uses

  • Uncomplicated gonococcal urethritis in males.[2]
  • Bacterial infections in the gastrointestinal system.[2]
  • Genitourinary tract infections.[2]
  • Gonorrhoeae. however this indication is no longer effective due to bacterial resistance.[3]

Pefloxacin has been increasingly used as a veterinary medicine to treat microbial infections.[4]

Mode of action

Pefloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV,[5] which is an enzyme necessary to separate, replicated DNA, thereby inhibiting cell division.

Adverse effects

Tendinitis and rupture, usually of the Achilles tendon, are a class-effects of the fluoroquinolones, most frequently reported with pefloxacin.[6] The estimated risk of tendon damage during pefloxacin therapy has been estimated by the French authorities in 2000 to be 1 case per 23,130 treatment days as compared to ciprofloxacin where it has been estimated to be 1 case per 779,600.[7]

References

  1. http://www.bailii.org/ew/cases/EWHC/Patents/2008/2413.html
  2. 2.0 2.1 2.2 http://www.pefloxacin.com/pefloxacin_usage.htm
  3. Lua error in package.lua at line 80: module 'strict' not found.
  4. http://www.pefloxacin.com/pefloxacin_other.html
  5. Lua error in package.lua at line 80: module 'strict' not found.
  6. Lua error in package.lua at line 80: module 'strict' not found.
  7. Lua error in package.lua at line 80: module 'strict' not found.

External links